PURPOSE
Despite significant advances in melanoma treatment, many survivors continue to experience long-term effects of disease and therapy. Various survivorship care programs have been developed in recent years, but these differ in terms of their scope, content, and delivery. The aim of this scoping review was to summa...
Madlen Hörold, Sasha Schutkowski, K. Drewitz et al.· Journal of cancer survivorsh...· 0 citations
Robust long‐term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10‐year melanoma‐specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain...
Markus Reitmajer, S. Dugas-Breit, C. Blomen et al.· Journal der Deutschen Dermat...· 0 citations
This review provides a comprehensive overview of SGC entities and summarizes current knowledge of their mutational landscapes to improve understanding of their biology and identify potential therapeutic targets, particularly for aggressive tumors lacking treatment options in advanced stages.
Lara Racz, A. Böer-Auer, F. Meier et al.· European Journal of Cancer· 0 citations
It is demonstrated that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.
J. Winterstein, L. Heinlein, G. Raddatz et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.